Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Essential Pharmacogenomic Biomarkers in Clinical Practice
69
44. Solus JF, Arietta BJ, Harris JR, et al. Genetic variation in eleven phase I drug metabolism
genes in an ethnically diverse population. Pharmacogenomics 2004;5:895–931.
45. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive
review of the in-vitro and human data. Pharmacogenetics 2002;12:251–63.
46. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation
Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
Clinical Pharmacology and Therapeutics 2011;90:625–9.
47. Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP: An update
of pharmacovigilance efforts conducted by independent researchers, pharmaceutical
suppliers, and the Food and Drug Administration. Stroke; A Journal of Cerebral
Circulation 2004;35:533–7.
48. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response
to clopidogrel. The New England Journal of Medicine 2009;360:354–62.
49. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response
to clopidogrel and cardiovascular events. The New England Journal of Medicine
2009;360:363–75.
50. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of
adverse clinical outcomes among patients treated with clopidogrel predominantly for
PCI: A meta-analysis. JAMA 2010;304:1821–30.
51. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young
patients treated with clopidogrel after myocardial infarction: A cohort study. The
Lancet 2009;373:309–17.
52. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel
metabolism, platelet function, and cardiovascular events: A systematic review and
meta-analysis. JAMA 2011;306:2704–14.
53. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact
of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with
clopidogrel: Systematic review and meta-analysis. BMJ (Clinical Research Edition)
2011;343:d4588.
54. Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS. Management of dyslipidemia
and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.
Vascular Health and Risk Management 2013;9:273–82.
55. Armitage J. The safety of statins in clinical practice. The Lancet 2007;370:1781–90.
56. Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. Study of the effectiveness
of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics
of a randomized trial among 12064 myocardial infarction survivors. American Heart
Journal 2007;154:815–23, 23 e1–6.
57. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy—
A genomewide study. The New England Journal of Medicine 2008;359:789–99.
58. Daly AK. Using genome-wide association studies to identify genes important in serious
adverse drug reactions. Annual Review of Pharmacology and Toxicology 2012;
52:21–35.
59. Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Annals of Internal Medicine
1984;100:704–13.
60. Yasui N, Adachi N, Kato M, et al. Cisplatin-induced hearing loss: The need for a longterm
evaluating system. Journal of Pediatric Hematology/Oncology 2014;36:e241–5.
61. Waissbluth S, Daniel SJ. Cisplatin-induced ototoxicity: Transporters playing a role in
cisplatin toxicity. Hearing Research 2013;299:37–45.
62. Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms
may influence chemotherapy response and disease outcome in osteosarcoma:
A pilot study. Cancer 2012;118:1856–67.